Orion Corporation: Managers’ transactions – Virve Laitinen

ORION CORPORATION

MANAGERS’ TRANSACTIONS

4 MARCH 2024 at 13.00 EET

        

Orion Corporation: Managers’ transactions – Virve Laitinen

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Virve Laitinen

Position: Other senior manager

Issuer: Orion Oyj

LEI: 74370029VAHCXDR7B745

Notification type: INITIAL NOTIFICATION

Reference number: 54274/5/4

____________________________________________

Transaction date: 2024-03-01

Outside a trading venue

Instrument type: SHARE

ISIN: FI0009014377

Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE

Transaction details

(1): Volume: 7282 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 7282 Volume weighted average price: 0 EUR

Orion Corporation

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.